VALN

5.1603.82%
PB

Peter Buhler

Chief Financial Officer

Mr. Peter Buhler serves as Chief Financial Officer at Valneva SE from January 2022 and was its Member of Management Board until December 20, 2023. He was Chief Financial Officer of Quotient Limited from February 5, 2020 until November 1, 2021. Mr. Buhler has immense financial experience gained through various roles in industry and public accounting. From 2017 to 2019, Mr. Buhler served as Group Chief Financial Officer at Zaluvida Corporate AG, a life sciences company focused on obesity, antibiotic resistance and other global health challenges. From 2013 to 2017, Mr. Buhler served as Group Chief Financial Officer for Stallergenes Greer SA, a global life sciences company focused on allergy immunotherapy, where he led a complex merger project combining a French and a U.S. group. From 2010 to 2013, Mr. Buhler was Finance Director of EMEA for Logitech International SA. From 2008 to 2010, Mr. Buhler was Chief Financial Officer at Anteis SA, a mid-sized medical technology company. From 2001 to 2008, Mr. Buhler served various roles at Merck Serono, a biopharmaceutical company, including Head of Finance Commercial Europe and Senior Director of Corporate Strategic Development. From 1999 to 2001, Mr. Buhler was Manager General Accounting and Control for a division of Eli Lilly and Company. Prior to that, Mr. Buhler spent over many years in public accounting with BDO Visura. Mr. Buhler is a Swiss Chartered Accountant, a member of the Swiss Institute of Certified Accountants and Tax Consultants and received an MBA from SBS Swiss Business School.

Positions